Elevation Oncology ELEV 深 沪
等待开盘 07-30 09:30:00 美东时间
0.365
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.365
- 总市值 2161.67万
- 52周最高 2.2599
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.221
- 委 比 0.00%
- 总股本 5922.37万
- 历史最高 16.22
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.221
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA vaccines head, chief medical officer Vinay Prasad departs agency
Vinay Prasad, who headed the U.S. FDA division in charge of vaccines and was also chief medical and scientific officer, has abruptly left the agency. He joined the FDA in May as director of the Center...
今天 15:00
Sarepta Therapeutics shares are trading higher after the company announced ELEVIDYS was not linked to a recent patient death in Brazil.
Sarepta Therapeutics shares are trading higher after the company announced ELEV...
07-28 22:39
Arrowhead expects Sarepta to honor financial obligations
Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced Wednesday that it expects its partner Sarepta Therapeutics (NASDAQ:SRPT), which recently withdrew its gene therapy Elevidys from the U.S. market, will...
07-23 22:25
Elevation Oncology Completes Merger with Concentra Biosciences
Elevation Oncology ( ($ELEV) ) has issued an update. Elevation Oncology, Inc. a...
07-23 21:48
Sarepta to pause Elevidys gene therapy shipments in U.S.
Sarepta Therapeutics (NASDAQ:SRPT) said late Monday it will pause all shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, in the U.S. The development comes after Sarepta declined to h...
07-22 13:35
Sarepta shares cut to $0 at H.C. Wainwright
H.C. Wainwright has taken the unusual step of setting a $0 price target for troubled biotech Sarepta Therapeutics (NASDAQ:SRPT). The firm, which rates the stock a sell, previously had a $10 price targ...
07-22 01:59
Sarepta拒绝FDA撤回药物的要求，其股价持续下滑
核心要点 索雷帕塔治疗公司（Sarepta Therapeutics）拒绝了美国食品药品监督管理局（FDA）关于停止其肌肉萎缩症药物发货的要求。 美国食品药品...
07-21 23:09
Sarepta Announces Strategic Restructuring With 36% Workforce Reduction And $400M In Annual Cost Savings, Refocuses Pipeline On siRNA Assets; Reports $513M In Q2 Revenue And Resolving FDA Issues For ELEVIDYS
– After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets– Strategic restructuring includes reduced operating expenses, delivering
07-17 04:03
